Deutsche Bank Reiterates Buy, $57 PT on Gilead Sciences

Loading...
Loading...
Deutsche Bank remains Buy-rated with a $57 target price on Gilead Sciences
GILD
following IMS Week-7 scripts analysis, which suggests higher price realization on the company's HIV franchise. Deutsche Bank says, "GILD took price increases for its HIV franchise on Jan 1st 2012. Price increases in 1Q'12 were Atripla 6.5%, Truvada 7.9%, Viread 4.9% and Complera 7.3%. These increases are additive to the first quarter. We have adjusted the price increase by drug to reflect the discounts in the channel due to ADAPs and public payers. This results in 73% of the full price passed through on GILD's HIV drugs. TRx increase/decrease + adj. price growth." GILD closed at $45.26 a share on Friday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationIntraday UpdateAnalyst RatingsDeutsche Bank
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...